# Delta-9-Tetrahydrocannabinol alleviates doxorubicin-induced weight loss but does not affect dextran sodium sulphate-induced colitis

**Authors:** Malene Wiborg Johansen, Maria C. E. Andersen, Thomas Nissen, Anders B. Nexoe, Seyda Ünsal, Gunvor I. Madsen, Sören Möller, Jens Kjeldsen, Grith Lykke Sorensen, Uffe Holmskov, Steffen Husby, Mathias Rathe

PMC · DOI: 10.1186/s42238-026-00386-z · Journal of Cannabis Research · 2026-01-14

## TL;DR

THC reduces weight loss from chemotherapy but does not help with intestinal inflammation or colitis in mice.

## Contribution

THC's effect on chemotherapy-induced weight loss is identified, but no benefit for colitis.

## Key findings

- THC reduced doxorubicin-induced weight loss in mice.
- THC increased small intestine length in doxorubicin-treated mice.
- THC had no effect on DSS-induced colitis or intestinal inflammation.

## Abstract

Gastrointestinal mucositis is a common adverse effect of chemotherapy. Inflammatory bowel diseases (IBD) are a spectrum of chronic inflammatory disorders of the digestive tract. Mucositis and IBD/colitis are characterized by weight loss and intestinal inflammation. Previous animal studies suggest that the cannabinoid, ∆9-tetrahydrocannabinol (THC), attenuates intestinal inflammation. We aimed to investigate the effect of THC oil on doxorubicin-induced gastrointestinal mucositis and dextran sodium sulphate (DSS) induced colitis in mice.

Wild-type C57BL6 mice were used for the experiments. The mice received a daily dose of THC oil at either 10 mg/kg or 20 mg/kg or vehicle by oral gavage. Mucositis was induced by intraperitoneal injection of doxorubicin, while colitis was induced by supplementing the drinking water with 2% DSS. Gastrointestinal toxicity was evaluated by weight, intestinal lengths, histopathological evaluation, and expression of genes related to chemotherapy-induced mucositis and intestinal inflammation.

Treatment with THC significantly reduced weight loss and increased the length of the small intestine in the doxorubicin-treated mice. No effects on gene expression of pro-inflammatory cytokines were observed. No effect of THC was observed in DSS-induced colitis.

THC reduced doxorubicin-induced weight loss, possibly due to increased appetite, but did not affect doxorubicin-induced intestinal inflammation or DSS-induced colitis in mice.

## Linked entities

- **Chemicals:** doxorubicin (PubChem CID 31703), Delta-9-Tetrahydrocannabinol (PubChem CID 2978), THC (PubChem CID 16078)
- **Diseases:** gastrointestinal mucositis (MONDO:0000888), colitis (MONDO:0005292)

## Full-text entities

- **Diseases:** weight loss (MESH:D015431), colitis (MESH:D003092)
- **Chemicals:** dextran sodium sulphate (-), doxorubicin (MESH:D004317), Delta-9-Tetrahydrocannabinol (MESH:D013759)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12888137/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12888137/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12888137/full.md

---
Source: https://tomesphere.com/paper/PMC12888137